ʻO Helio Health, kahi hui mālama ola i alakaʻi ʻia e AI e kālele ana i ka hoʻolaha ʻana i nā hoʻokolohua ʻike maʻi maʻi maʻi maʻi mai kahi huki koko maʻalahi, i kēia lā ua hoʻolaha ʻo Hepatology Communications i nā hopena maikaʻi mai ka haʻawina ENCORE e hōʻoia ana i ka hana lapaʻau ikaika o HelioLiver i ka ʻike ʻana i ka hiki ʻana mai o ka maʻi hepatocellular carcinoma (HCC) , ka 'ano ma'amau o ka ma'i 'a'ai a me ka 'ehiku o ka ma'i 'a'ai ma'amau ma ka honua holo'oko'a akā 'o ka lua o ka ma'i 'a'ai e pili ana i ka ma'i 'a'ai, pinepine ma muli o ka lohi 'ana. %) a me ka noʻonoʻo kiʻekiʻe (1%) i ka ʻike ʻana i ka wā mua (pae I a me II) HCC, ʻoi aku ka maikaʻi ma mua o nā mea hana ʻike maʻi ʻē aʻe e like me AFP (2%), GALAD (91%), a me ultrasound (76%). 57 Ke noʻonoʻo nei i ka HCC holoʻokoʻa, ua hana ʻo HelioLiver ma kahi 65% sensitivity me ka 47% specificity.2,3
| ʻO nā hoʻokolohua HCC Diagnostic | Ka Papa Mua (I + II). | ʻO ka noʻonoʻo āpau |
| Heliline Maililiver2 | 76% | 85% |
| AFP (≥ 20 NG / ML)2 | 57% | 62% |
| Helu GALAD (≥ -0.63)2 | 65% | 75% |
| 'Ohanahana3 | 47% | 84% |
| 'Ōlelo Aʻo: Hōʻike ka papa ʻaina i ka ʻike HelioLiver ma 91% kikoʻī2 | ||
| 2 Lin n, et al. 2021. | ||
| 3 Tzartzeva k, et al. 2018. |
Ua hoʻomohala ʻo Helio i kāna papa hana hoʻopulapula e hiki mai ana, ʻo ECLIPSETM, e ʻike i nā pahuhopu methylation 77 ma waena o 28 genes. Ke hana nei kēia mau hōʻailona DNA me ka serum HCC proteins AFP, AFP-L3%, a me DCP e hoʻonui i ka algorithm multi-analyte.
• ʻO 0.944 ka wahi ma lalo o ke ʻano hana hoʻokipa (AUROC) no HelioLiver, e hōʻike ana i ka hiki ke wānana ʻoi aku ka maikaʻi ma mua o nā hoʻokolohua ʻē aʻe.
• Ma kahi kikoʻī paʻa o 87.5%, ua loaʻa iā HelioLiver i ka 87% sensitivity no ka HCC mua a me 90% sensitivity holoʻokoʻa.
• 10 o ka 28 genes i hoʻohana 'ia ma ka HelioLiver ho'āʻo i loaʻa i ka pili pono i loko o ka molecular ala i ike i implicated i loko o HCC pathogenesis oiai hoʻokahi wale nō o ka investigated akā unselected 497 genes i halawai me ka like nā pae hoʻohālike, e manao ana i na markers ma HelioLiver oi aku. pili olaola ma mua o nā ho'āʻo e hoʻohana ana i kēia mau genes ʻē aʻe.
ʻO ka Hepatology Communications ka puka wehe ākea, loiloi ʻia e nā hoa o ka American Association for the Study of Liver Diseases (AASLD), i hoʻolaʻa ʻia i ka hoʻolaha wikiwiki ʻana o ka noiʻi kiʻekiʻe ma ka hepatology. ʻO AASLD ka hui alakaʻi lapaʻau i mahalo nui ʻia no ka maʻi ate ma ʻAmelika Hui Pū ʻIa.
Ke hoʻomau nei ʻo HelioLiver i ka loiloi hou ʻana ma ke ʻano he ʻāpana o ka Helio pivotal, prospective biomarker study, CLiMB (NCT03694600), kahi e hoʻohālikelike pono ʻia ka hana o ka hoʻāʻo me ka ultrasound me ka hoʻohana ʻana i ka MRI multi-phasic e like me ke ʻano o ka mālama ʻana i ka maʻi HCC.
He aha e lawe ʻia mai kēia ʻatikala:
- ʻO Helio Health, he hui mālama ola i alakaʻi ʻia e AI e kālele ana i ka kūʻai ʻana i nā hoʻokolohua ʻike maʻi maʻi maʻi maʻi mai kahi huki koko maʻalahi, i kēia lā ua hoʻolaha ʻo Hepatology Communications i nā hopena maikaʻi mai ka haʻawina ENCORE e hōʻoia ana i ka hana lapaʻau ikaika o HelioLiver i ka ʻike ʻana i ka hiki ʻana o ka maʻi hepatocellular carcinoma (HCC) , ka 'ano ma'amau o ka ma'i 'a'ai a me ka 'ehiku o ka ma'i 'a'ai ma'amau ma ka honua holo'oko'a akā 'o ka lua o ka ma'i 'a'ai e pili ana i ka ma'i 'a'ai, pinepine ma muli o ka ma'i ma'i lohi.
- Ua ʻike ʻia he 10 o nā genes 28 i hoʻohana ʻia i ka hoʻāʻo HelioLiver e pili pono ana i nā ala molecular i ʻike ʻia e pili ana i ka pathogenesis HCC ʻoiai hoʻokahi wale nō o nā genes 497 i noiʻi ʻia akā koho ʻole ʻia i hoʻokō i nā pae like, e hōʻike ana he ʻoi aku ka biologically o nā māka ma HelioLiver. kūpono ma mua o nā hoʻokolohua e hoʻohana ana i kēia mau genes ʻē aʻe.
- Ke hoʻomau nei ʻo HelioLiver i ka loiloi hou ʻana ma ke ʻano he ʻāpana o ka Helio pivotal, prospective biomarker study, CLiMB (NCT03694600), kahi e hoʻohālikelike pono ʻia ka hana o ka hoʻāʻo me ka ultrasound me ka hoʻohana ʻana i ka MRI multi-phasic e like me ke ʻano o ka mālama ʻana i ka maʻi HCC.
